Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYH2051 Monotherapy and with Radiotherapy in Advanced Tumors
NCT06011291Phase 1Recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Aug 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SYH2051 in solid tumor and head and neck cancer (HNC) (3 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Incidence of dose-limiting toxicities at 11 weeks, Incidence of adverse events and serious adverse events at 2 years and 2 more. Started Aug 2023; status: recruiting.
02
Drugs
SYH2051
03
Conditions
solid tumorhead and neck cancer (HNC)
Beyond the preview
Go deeper on NCT06011291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06011291.